PDF(1199 KB)
Effect of PD-L1 on proliferation, migration, and invasion of human oral squamous carcinoma cells
Jie ZENG,Xueyan YU,Ting LUO,Jiang XU
PDF(1199 KB)
PDF(1199 KB)
Effect of PD-L1 on proliferation, migration, and invasion of human oral squamous carcinoma cells
)Objective To discuss the expression of programmed cell death-ligand 1 （PD-L1） in the oral squamous cell carcinoma （OSCC） cells and its effect on biological behavior of the OSCC CAL27 cells， and to clarify the possible mechanism. Methods Western blotting method was used to detect the expression levels of PD-L1 protein in the oral epithelial HOK cells and OSCC CAL27， TCA8113， and SCC15 cells； immunofluorescence staining method was used to detect the expression and localization of PD-L1 protein in the CAL27 cells. The CAL27 cells were divided into control group （transfected with si-NC） and si-PD-L1 group （transfected with si-PD-L1）. Western blotting method was used to detect the interference efficiency of the cells in two groups； CCK-8 assay was used to detect the proliferative activities of the cells in two groups at different time points； plate clone formation assay was used to detect the numbers of clone formation of the cells in two groups； cell scratch healing assay was used to detect the scratch healing rates of the cells in two groups； Transwell chamber assay was used to detect the numbers of migration and invasion cells in two groups. Results The expression level of PD-L1 protein in the OSCC cells was higher than that in the HOK cells （P<0.05 or P<0.01）； PD-L1 expressed in the cytoplasm and nucleus of the CAL27 cells. The CCK-8 assay and plate clone formation assay results showed that compared with control group， the proliferative activities of the CAL27 cells in si-PD-L1 group at different time points were significantly decreased（P<0.05 or P<0.01）， and the numbers of clone formation were significantly decreased （P<0.01）. The cell scratch healing assay results showed that compared with control group， the scratch healing rates of the cells in si-PD-L1 group were significantly decreased （P<0.05 or P<0.01）. The Transwell chamber assay results showed that compared with control group， the numbers of migration and invasion cells in si-PD-L1 group were significantly decreased （P<0.01）. Conclusion The expression of PD-L1 in the OSCC cells is higher than that in normal oral epithelial cells， and knocking down PD-L1 expression can inhibit the proliferation， clone formation， migration and invasion capabilities of the OSCC cells.
Oral squamous cell carcinoma / Programmed cell death-ligand 1 / Cell proliferation / Cell migration / Cell invasion
R739.8
| 1 | CHAVES F N， BEZERRA T M M， MORAES D C， et al. Loss of heterozygosity and immunoexpression of PTEN in oral epithelial dysplasia and squamous cell carcinoma［J］. Exp Mol Pathol， 2020， 112： 104341. |
| 2 | 李玮柏， 曹 娟， 郭 秀， 等. 肿瘤相关巨噬细胞来源IL-6通过上调肿瘤细胞中LIF表达对口腔鳞状细胞癌CAL27细胞侵袭和迁移的促进作用［J］. 吉林大学学报（医学版）， 2022， 48（4）： 946-953. |
| 3 | PRINCIPE S， ZAPATER-LATORRE E， ARRIBAS L，et al. Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients［J］. Clin Oral Investig， 2022， 26（1）： 437-448. |
| 4 | DAVE K， ALI A， MAGALHAES M. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma： a pilot study［J］. Sci Rep， 2020， 10（1）： 9705. |
| 5 | CROCE C M. Causes and consequences of microRNA dysregulation in cancer［J］.Nat Rev Genet，2009，10（10）： 704-714. |
| 6 | YU Y， CAO X C. miR-190-5p in human diseases［J］. Cancer Cell Int， 2019， 19： 257. |
| 7 | 田国永， 鹿国英， 吕志军， 等. PD-1、PD-L1在口腔鳞状细胞癌中表达意义及对疾病预后价值研究［J］. 实用口腔医学杂志， 2021， 37（6）： 841-844. |
| 8 | ZHANG Y H， WANG A F， ZHANG X H， et al. lncRNA LINC01296 promotes oral squamous cell carcinoma development by binding with SRSF1［J］. Biomed Res Int， 2021， 2021： 6661520. |
| 9 | SUN S， WANG J， LIU J， et al. miR-302b suppresses tumor metastasis by targeting Frizzled6 in OSCC［J］. J Dent Res， 2021， 100（7）： 739-745. |
| 10 | CHA J H， CHAN L C， LI C W， et al. Mechanisms controlling PD-L1 expression in cancer［J］. Mol Cell， 2019， 76（3）： 359-370. |
| 11 | WHITESIDE T L. Head and neck carcinoma immunotherapy： facts and hopes［J］. Clin Cancer Res， 2018， 24（1）： 6-13. |
| 12 | JIANG Y S， CHEN M， NIE H， et al. PD-1 and PD-L1 in cancer immunotherapy： clinical implications and future considerations［J］.Hum Vaccin Immunother，2019，15（5）：1111-1122. |
| 13 | TANG Q， CHEN Y， LI X J， et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers［J］. Front Immunol， 2022， 13： 964442. |
| 14 | ZHENG B X， REN T T， HUANG Y， et al. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3［J］. Biochem Biophys Res Commun， 2018， 495（2）： 1695-1701. |
| 15 | NIU M K， LIU Y M， YI M， et al. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer［J］. Front Immunol， 2022， 13： 827921. |
| 16 | HU X L， WANG J， CHU M， et al. Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy［J］. Mol Ther， 2021， 29（3）： 908-919. |
| 17 | 程 然， 徐小元. PD-1/PD-L1免疫抑制剂在HBV感染相关肝细胞癌中的有效性及安全性分析［J］. 临床肝胆病杂志， 2022，38（9）： 2160-2164. |
| 18 | 李 林， 杨双宁， 秦国慧， 等. 基于UHPLC-Q-Orbitrap HRMS的PD-1抑制剂治疗的晚期肺腺癌患者血清代谢组学研究［J］. 郑州大学学报（医学版）， 2022，57（5）： 631-634. |
| 19 | LIU S W， CHEN S， YUAN W G， et al. PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways［J］. Oncotarget， 2017， 8（59）： 99901-99912. |
| 20 | MU L S， YU W T， SU H L， et al. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer［J］. Artif Cells Nanomed Biotechnol， 2019， 47（1）： 1036-1042. |
| 21 | 赵丽丽， 赵文文， 赵文飞， 等. 沉默PD-L1基因表达抑制胃癌细胞黏附、迁移、侵袭及上皮间质转化［J］. 现代肿瘤医学， 2022， 30（15）： 2716-2722. |
| 22 | QU Q X， XIE F， HUANG Q， et al. Membranous and cytoplasmic expression of PD-L1 in ovarian cancer cells［J］. Cell Physiol Biochem，2017，43（5）：1893-1906. |
| 23 | YANG S J， ZHANG Q Y， LIU S， et al. PD-1， PD-L1 and PD-L2 expression in mouse prostate cancer［J］. Am J Clin Exp Urol， 2016， 4（1）： 1-8. |
/
| 〈 |
|
〉 |
AI Summary
